Cargando…
Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker so...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346584/ https://www.ncbi.nlm.nih.gov/pubmed/25729848 http://dx.doi.org/10.1371/journal.pone.0118200 |
_version_ | 1782359713484111872 |
---|---|
author | Roland, Wibke S. U. Sanders, Marijn P. A. van Buren, Leo Gouka, Robin J. Gruppen, Harry Vincken, Jean-Paul Ritschel, Tina |
author_facet | Roland, Wibke S. U. Sanders, Marijn P. A. van Buren, Leo Gouka, Robin J. Gruppen, Harry Vincken, Jean-Paul Ritschel, Tina |
author_sort | Roland, Wibke S. U. |
collection | PubMed |
description | The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker software, which has been used successfully before for drug design of GPCRs of the rhodopsin subfamily. For the validation of the model, two sets of compounds, both of which contained actives and inactives, were used: (i) an (iso)flavonoid-dedicated set, and (ii) a more generic, structurally diverse set. Agonists were characterized by their linear binding geometry and the fact that they bound deeply in the hTAS2R39 pocket, mapping the hydrogen donor feature based on T5.45 and N3.36, analogues of which have been proposed to play a key role in activation of GPCRs. Blockers lack hydrogen-bond donors enabling contact to the receptor. Furthermore, they had a crooked geometry, which could sterically hinder movement of the TM domains upon receptor activation. Our results reveal characteristics of hTAS2R39 agonist and bitter blocker binding, which might facilitate the development of blockers suitable to counter the bitterness of dietary hTAS2R39 agonists in food applications. |
format | Online Article Text |
id | pubmed-4346584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43465842015-03-17 Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 Roland, Wibke S. U. Sanders, Marijn P. A. van Buren, Leo Gouka, Robin J. Gruppen, Harry Vincken, Jean-Paul Ritschel, Tina PLoS One Research Article The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker software, which has been used successfully before for drug design of GPCRs of the rhodopsin subfamily. For the validation of the model, two sets of compounds, both of which contained actives and inactives, were used: (i) an (iso)flavonoid-dedicated set, and (ii) a more generic, structurally diverse set. Agonists were characterized by their linear binding geometry and the fact that they bound deeply in the hTAS2R39 pocket, mapping the hydrogen donor feature based on T5.45 and N3.36, analogues of which have been proposed to play a key role in activation of GPCRs. Blockers lack hydrogen-bond donors enabling contact to the receptor. Furthermore, they had a crooked geometry, which could sterically hinder movement of the TM domains upon receptor activation. Our results reveal characteristics of hTAS2R39 agonist and bitter blocker binding, which might facilitate the development of blockers suitable to counter the bitterness of dietary hTAS2R39 agonists in food applications. Public Library of Science 2015-03-02 /pmc/articles/PMC4346584/ /pubmed/25729848 http://dx.doi.org/10.1371/journal.pone.0118200 Text en © 2015 Roland et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Roland, Wibke S. U. Sanders, Marijn P. A. van Buren, Leo Gouka, Robin J. Gruppen, Harry Vincken, Jean-Paul Ritschel, Tina Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title | Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title_full | Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title_fullStr | Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title_full_unstemmed | Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title_short | Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 |
title_sort | snooker structure-based pharmacophore model explains differences in agonist and blocker binding to bitter receptor htas2r39 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346584/ https://www.ncbi.nlm.nih.gov/pubmed/25729848 http://dx.doi.org/10.1371/journal.pone.0118200 |
work_keys_str_mv | AT rolandwibkesu snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT sandersmarijnpa snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT vanburenleo snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT goukarobinj snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT gruppenharry snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT vinckenjeanpaul snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 AT ritscheltina snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39 |